ENTRY       D01161                      Drug
NAME        Fulvestrant (JAN/USAN/INN);
            Faslodex (TN)
PRODUCT     FASLODEX (AstraZeneca Pharmaceuticals LP) 83d7a440-e904-4e36-afb5-cb02b1c919f7
FORMULA     C32H47F5O3S
EXACT_MASS  606.3166
MOL_WEIGHT  606.7708
CLASS       Antineoplastic
             DG01585  Estrogen receptor antagonist
REMARK      Therapeutic category: 4291
            ATC code: L02BA03
ACTIVITY    Antineoplastic, Estrogen receptor agonist/antagonist
  DISEASE   Breast cancer (postmenopausal, ER positive) [DS:H00031]
TARGET      NR3A1 (ESR1) [HSA:2099] [KO:K08550];
            NR3A2 (ESR2) [HSA:2100] [KO:K08551]
METABOLISM  Enzyme: CYP3A4 [HSA:1576]
INTERACTION Genomic biomarker: ESR [HSA:2099 2100]
STR_MAP     map07043  Antineoplastics - hormones
            map07226  Progesterone, androgen and estrogen receptor agonists/antagonists
OTHER_MAP   map01522  Endocrine resistance
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
              L02 ENDOCRINE THERAPY
               L02B HORMONE ANTAGONISTS AND RELATED AGENTS
                L02BA Anti-estrogens
                 L02BA03 Fulvestrant
                  D01161  Fulvestrant (JAN/USAN/INN)
            Therapeutic category of drugs in Japan [BR:br08301]
             4  Agents affecting cellular function
              42  Antineoplastics
               429  Miscellaneous
                4291  Other Antitumors
                 D01161  Fulvestrant (JAN/USAN/INN)
            Target-based classification of drugs [BR:br08310]
             Nuclear receptors
              Estrogen like receptors
               Estrogen receptor
                estrogen receptor 1
                 Fulvestrant
                  D01161  Fulvestrant (JAN/USAN/INN)
                estrogen receptor 2
                 Fulvestrant
                  D01161  Fulvestrant (JAN/USAN/INN)
            Antineoplastics [br08340.html]
             D01161
            New drug approvals in the USA [br08319.html]
             New Molecular Entity and New Therapeutic Biological Product Approvals
              D01161
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D01161
            New drug approvals in Japan [br08318.html]
             Drugs with new active ingredients
              D01161
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D01161
            Pharmacogenomic biomarkers in FDA drug labels [br08341.html]
             Companion diagnostics
              D01161
DBLINKS     CAS: 129453-61-8
            PubChem: 7848224
            ChEBI: 31638
            ChEMBL: CHEMBL1358
            DrugBank: DB00947
            PDB-CCD: FVS
            LigandBox: D01161
            NIKKAJI: J401.163E
ATOM        41
            1   C8x C     7.4203  -16.5528
            2   C8y C     7.4203  -17.9330
            3   C8x C     8.6185  -18.6231
            4   C8x C     8.6185  -15.8628
            5   C8y C     9.8096  -16.5528
            6   C8y C     9.8037  -17.9330
            7   C1x C    10.9960  -18.6281
            8   C1y C    12.1942  -17.9432
            9   C1y C    11.0077  -15.8679
            10  C1y C    12.1942  -16.5658
            11  C1x C    12.2169  -13.8129
            12  C1x C    11.0191  -14.4913
            13  C1z C    13.4035  -14.5109
            14  C1y C    13.3866  -15.8831
            15  C1x C    15.7638  -15.9121
            16  C1x C    15.7803  -14.5396
            17  C1y C    14.6003  -13.8392
            18  O1a O    14.7331  -12.4541
            19  O1a O     6.2253  -18.6237
            20  C1b C    13.3801  -18.6301
            21  C1b C    14.5721  -17.9469
            22  C1b C    15.7641  -18.6370
            23  C1b C    16.9561  -17.9539
            24  C1b C    18.1480  -18.6440
            25  C1b C    19.3400  -17.9609
            26  C1b C    20.5319  -18.6510
            27  C1b C    21.7239  -17.9678
            28  C1b C    22.9159  -18.6579
            29  S4a S    24.1078  -17.9748
            30  C1b C    25.2998  -18.6649
            31  C1b C    26.4917  -17.9819
            32  C1b C    27.6837  -18.6720
            33  C1d C    28.8756  -17.9887
            34  O3c O    24.1108  -16.5946
            35  X   F    29.9914  -17.2156
            36  X   F    27.8928  -17.0058
            37  C1a C    13.3941  -13.1303
            38  C1d C    29.8649  -18.9778
            39  X   F    30.8541  -19.9671
            40  X   F    31.0764  -18.2784
            41  X   F    28.6534  -19.6773
BOND        44
            1     4   1 1
            2     2  19 1
            3     1   2 2
            4     8  20 1 #Down
            5     9  10 1
            6    20  21 1
            7    10  14 1
            8    21  22 1
            9    13  11 1
            10   22  23 1
            11   11  12 1
            12   23  24 1
            13   12   9 1
            14   24  25 1
            15    2   3 1
            16   25  26 1
            17    3   6 2
            18   26  27 1
            19    5   6 1
            20   27  28 1
            21    6   7 1
            22   28  29 1
            23    7   8 1
            24   29  30 1
            25   13  14 1
            26   30  31 1
            27   15  16 1
            28   31  32 1
            29   16  17 1
            30   32  33 1
            31   17  13 1
            32   29  34 2
            33   14  15 1
            34    8  10 1
            35   17  18 1 #Up
            36    9   5 1
            37   33  35 1
            38    5   4 2
            39   33  36 1
            40   13  37 1 #Up
            41   33  38 1
            42   38  39 1
            43   38  40 1
            44   38  41 1
///
